Starling Oncology annual stock-based compensation
2020
2021
2022
2023
2024
2025
Starling Oncology Stock-Based Compensation Growth & History (STLN)
Starling Oncology's stock-based compensation was $4.6M for fiscal 2025.
View full Starling Oncology company overviewStarling Oncology annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.6M | −$6.6M | −59.19% |
| 2024 | 2024-12-31 | $11.2M | −$6.7M | −37.38% |
| 2023 | 2023-12-31 | $17.8M | −$9.9M | −35.66% |
| 2022 | 2022-12-31 | $27.7M | $3.1M | +12.83% |
| 2021 | 2021-12-31 | $24.5M | $24.4M | +16148.34% |
| 2020 | 2020-12-31 | $151,000 | — | — |
Starling Oncology quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.1M | $318,000 | +42.29% |
| Q1 2026 | 2026-03-31 | $1.7M | $228,000 | +15.64% |
| Q4 2025 | 2025-12-31 | $1.3M | $28,000 | +2.17% |
| Q3 2025 | 2025-09-30 | $1.0M | −$1.4M | −57.14% |
| Q2 2025 | 2025-06-30 | $752,000 | −$2.6M | −77.80% |
| Q1 2025 | 2025-03-31 | $1.5M | −$2.6M | −64.33% |
| Q4 2024 | 2024-12-31 | $1.3M | −$2.8M | −68.40% |
| Q3 2024 | 2024-09-30 | $2.4M | −$2.3M | −48.72% |
| Q2 2024 | 2024-06-30 | $3.4M | −$720,000 | −17.53% |
| Q1 2024 | 2024-03-31 | $4.1M | −$878,000 | −17.68% |
| Q4 2023 | 2023-12-31 | $4.1M | −$2.0M | −32.80% |
| Q3 2023 | 2023-09-30 | $4.7M | −$1.9M | −28.83% |
| Q2 2023 | 2023-06-30 | $4.1M | −$2.4M | −36.95% |
| Q1 2023 | 2023-03-31 | $5.0M | −$3.6M | −41.95% |
| Q4 2022 | 2022-12-31 | $6.1M | −$18.3M | −75.11% |
| Q3 2022 | 2022-09-30 | $6.5M | $6.5M | +10994.92% |
| Q2 2022 | 2022-06-30 | $6.5M | $6.5M | +12672.55% |
| Q1 2022 | 2022-03-31 | $8.6M | $8.5M | +20264.29% |
| Q4 2021 | 2021-12-31 | $24.4M | — | — |
| Q3 2021 | 2021-09-30 | $59,000 | — | — |
| Q2 2021 | 2021-06-30 | $51,000 | — | — |
| Q1 2021 | 2021-03-31 | $42,000 | — | — |
Starling Oncology stock-based compensation trends
Over the last five fiscal years, Starling Oncology's stock-based compensation increased from $151,000 to $4.6M, a change of $4.4M. The latest reported quarter, Q2 2026, shows $1.1M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Starling Oncology source filings ↗